Euroopan lääkevirasto EMA järjestää tiedotustilaisuuden Covid-19-pandemiasta 12.5. kello 15 Suomen aikaa.
Tiedotusvälineille suunnatun tilaisuuden tarkoituksena on antaa yleiskuva pandemian nykytilanteesta. Lyhyen esittelyn jälkeen koronarokotteiden ja hoitojen viimeaikaisesta kehityksestä pidetään kysymys-vastaus-osio.
Median edustajia pyydetään ilmoittautumaan ennakkoon: https://ema-europa.webex.com/ema-europa/j.php?RGID=rc52792629097252f93073230e0981757
Linkki tilaisuuteen Euroopan komission verkkosivuilla: https://audiovisual.ec.europa.eu/en/ebs/live/2
Linkki tilaisuuteen EMA:n YouTube-kanavan kautta: https://www.youtube.com/watch?v=fbd9r2YdxJ0
Ohessa EMA:n koko tiedote:
First EMA regular press briefing on COVID-19
The European Medicines Agency (EMA) is holding a press briefing to provide updates on its activities in the context of the COVID-19 pandemic. This is a technical briefing, intended to give an overview of the state-of-play of the current situation. Following a short introduction on recent developments relating to COVID-19 vaccines and treatments, the floor will be opened for a question-and-answer session.
These virtual briefings for the media will now be organised on a regular basis, initially every two weeks. They will be piloted until July 2021. During the pilot phase we invite your feedback and suggestions on this initiative.
As a complement to these regular technical briefings, EMA will still organise ad-hoc press conferences as necessary and appropriate.
WHEN: Wednesday, 12 May 2021 at 14:00-14:30 CET.
SPEAKERS: Marco Cavaleri (Head of Biological Health Threats and Vaccines Strategy)
Fergus Sweeney (Head of Clinical Studies and Manufacturing Task Force).
Georgy Genov (Head of Pharmacovigilance)
Marie-Agnes Heine, Head of Communication Department (moderator)
The press briefing will be held virtually via Webex. Please use the below link to register. Once registered you will receive the joining instructions by email.
https://ema-europa.webex.com/ema-europa/j.php?RGID=rc52792629097252f93073230e0981757
We strongly advise you to register in advance of the briefing to avoid delay in joining the meeting. Please note that we will admit you a few seconds prior to the start of the press briefing to the virtual meeting room.
The press briefing will be streamed via Europe by Satellite (live and video on demand). Please refer to copyright information here. The press briefing will also be streamed live via EMA's YouTube channel.
A transcript and video of the whole event will be available on the EMA website in the following days.
The press briefing is organised as a virtual meeting as our offices are currently closed for external visits and also journalists will not be able to enter. Therefore, we strongly advise all media to refrain from coming in person to the EMA building in Amsterdam. We will not be arranging interviews before or after the briefing.
Stock footage of the EMA building is available here.
Please note that the press briefing will be held in English. No translations will be provided.
More information on how EMA collects and processes personal information is available in our privacy statements for media professionals and for the organisation of meetings and events.
Follow us on Twitter: @EMA_News.
We look forward to welcoming you to the briefing.
Best wishes, EMA press office
Lääkealan turvallisuus- ja kehittämiskeskus Fimea valvoo ja kehittää lääkealaa sekä edistää lääkkeiden järkevää käyttöä väestön terveydeksi.
© Koodiviidakko Oy - Y-tunnus 1939962-1